Table 1. Preferential but reversible... | American Society of Hematology

Table 1.

Preferential but reversible reduction of BM and spleen primitive and mature progenitors in Fancc^−/− mice following IFN-γ treatment

Time following completion of IFN-γ treatment and progenitor	No. colonies per organ with progenitors in a femur (spleen progenitors), WT					*No. colonies per organ with progenitors in a femur (spleen progenitors), Fancc^−/−*
		IFN-γ, μg/kg/d					IFN-γ, μg/kg/d
		0	120	400	0	120	400
0 d
HPP-CFCs	4 580 ± 1 583	2 807 ± 886^*	2 061 ± 830^*	2 717 ± 1 115†	893 ± 417^*	303 ± 199^*
	(6 720 ± 1 287)	(3 278 ± 964^*)	(2 274 ± 832^*)	(1 667 ± 119†)	(176 ± 80^*)	(51 ± 24^*)
LPP-CFCs	31 537 ± 8 948	22 775 ± 5 812^*	10 639 ± 2 523^*	32 232 ± 5 471	10 894 ± 3 860^*	3 614 ± 2 340^*
	(20 589 ± 4 022)	(13 879 ± 2 404^*)	(8 067 ± 605^*)	(26 570 ± 1 193)	(2 033 ± 573^*)	(422 ± 27^*)
45 d
HPP-CFCs	3 753 ± 305	3 406 ± 408	3 237 ± 194	1 691 ± 415†	1 651 ± 192†	1 441 ± 145†
	(6 436 ± 1 403)	(5 820 ± 1 069)	(6 300 ± 1 208)	(1 724 ± 420†)	(1 486 ± 323†)	(1 571 ± 503†)
LPP-CFCs	36 331 ± 3 051	32 641 ± 5 902	35 802 ± 4 524	38 780 ± 1 800	28 553 ± 6 897	36 063 ± 2 873
	(32 034 ± 2 009)	(36 467 ± 3 246)	(30 680 ± 5 107)	(34 684 ± 3 567)	(39 857 ± 6 098)	(36 004 ± 3 946)
90 d
HPP-CFCs	4 278 ± 772	4 575 ± 1 038	4 861 ± 1 460	2 376 ± 405†	2 130 ± 256†	2 064 ± 445†
	(6 338 ± 479)	(6 747 ± 689)	(6 114 ± 2 017)	(2 372 ± 485†)	(2 544 ± 737†)	(2 237 ± 515†)
LPP-CFCs	30 338 ± 8 479	26 767 ± 6 897	30 114 ± 2 017	34 372 ± 1 885	32 004 ± 7 367	32 371 ± 5 005
	(40 312 ± 4 068)	(39 906 ± 2 940)	(36 785 ± 3 416)	(31 116 ± 4 957)	(29 709 ± 4 210)	(32 110 ± 5 416)

Time following completion of IFN-γ treatment and progenitor	No. colonies per organ with progenitors in a femur (spleen progenitors), WT					*No. colonies per organ with progenitors in a femur (spleen progenitors), Fancc^−/−*
		IFN-γ, μg/kg/d					IFN-γ, μg/kg/d
		0	120	400	0	120	400
0 d
HPP-CFCs	4 580 ± 1 583	2 807 ± 886^*	2 061 ± 830^*	2 717 ± 1 115†	893 ± 417^*	303 ± 199^*
	(6 720 ± 1 287)	(3 278 ± 964^*)	(2 274 ± 832^*)	(1 667 ± 119†)	(176 ± 80^*)	(51 ± 24^*)
LPP-CFCs	31 537 ± 8 948	22 775 ± 5 812^*	10 639 ± 2 523^*	32 232 ± 5 471	10 894 ± 3 860^*	3 614 ± 2 340^*
	(20 589 ± 4 022)	(13 879 ± 2 404^*)	(8 067 ± 605^*)	(26 570 ± 1 193)	(2 033 ± 573^*)	(422 ± 27^*)
45 d
HPP-CFCs	3 753 ± 305	3 406 ± 408	3 237 ± 194	1 691 ± 415†	1 651 ± 192†	1 441 ± 145†
	(6 436 ± 1 403)	(5 820 ± 1 069)	(6 300 ± 1 208)	(1 724 ± 420†)	(1 486 ± 323†)	(1 571 ± 503†)
LPP-CFCs	36 331 ± 3 051	32 641 ± 5 902	35 802 ± 4 524	38 780 ± 1 800	28 553 ± 6 897	36 063 ± 2 873
	(32 034 ± 2 009)	(36 467 ± 3 246)	(30 680 ± 5 107)	(34 684 ± 3 567)	(39 857 ± 6 098)	(36 004 ± 3 946)
90 d
HPP-CFCs	4 278 ± 772	4 575 ± 1 038	4 861 ± 1 460	2 376 ± 405†	2 130 ± 256†	2 064 ± 445†
	(6 338 ± 479)	(6 747 ± 689)	(6 114 ± 2 017)	(2 372 ± 485†)	(2 544 ± 737†)	(2 237 ± 515†)
LPP-CFCs	30 338 ± 8 479	26 767 ± 6 897	30 114 ± 2 017	34 372 ± 1 885	32 004 ± 7 367	32 371 ± 5 005
	(40 312 ± 4 068)	(39 906 ± 2 940)	(36 785 ± 3 416)	(31 116 ± 4 957)	(29 709 ± 4 210)	(32 110 ± 5 416)

n = 5.

P < .01 comparing treated and untreated mice in the same genotype.

P < .01 comparing Fancc^−/− and WT.